These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 3295315)
21. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627 [TBL] [Abstract][Full Text] [Related]
22. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. Kane JP; Malloy MJ; Ports TA; Phillips NR; Diehl JC; Havel RJ JAMA; 1990 Dec; 264(23):3007-12. PubMed ID: 2243428 [TBL] [Abstract][Full Text] [Related]
23. Combined therapy of niacin, colestipol, and fat-controlled diet in men with coronary bypass. Effect on blood lipids and apolipoproteins. Nessim SA; Chin HP; Alaupovic P; Blankenhorn DH Arteriosclerosis; 1983; 3(6):568-73. PubMed ID: 6651612 [TBL] [Abstract][Full Text] [Related]
24. Extracranial carotid arterial disease in patients with familial hypercholesterolemia and coronary artery disease treated with colestipol and nicotinic acid. Kuo PT; Toole JF; Schaaf JA; Jones A; Wilson AC; Kostis JB; Moreyra AE Stroke; 1987; 18(4):716-21. PubMed ID: 3299882 [TBL] [Abstract][Full Text] [Related]
25. Effect of lipid-lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography. Nash DT; Gensini G; Esente P Int J Cardiol; 1982; 2(1):43-55. PubMed ID: 7129689 [TBL] [Abstract][Full Text] [Related]
26. Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. Paterson RW; Paat JJ; Steele GH; Hathaway SC; Wong JG South Med J; 1994 Feb; 87(2):236-42. PubMed ID: 8115891 [TBL] [Abstract][Full Text] [Related]
27. Effect of lovastatin or niacin combined with colestipol and regression of coronary atherosclerosis. Brown BG Eur Heart J; 1992 Jul; 13 Suppl B():17-20. PubMed ID: 1644095 [TBL] [Abstract][Full Text] [Related]
29. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. Kane JP; Malloy MJ; Tun P; Phillips NR; Freedman DD; Williams ML; Rowe JS; Havel RJ N Engl J Med; 1981 Jan; 304(5):251-8. PubMed ID: 7003391 [TBL] [Abstract][Full Text] [Related]
30. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Zhao XQ; Brown BG; Hillger L; Sacco D; Bisson B; Fisher L; Albers JJ Circulation; 1993 Dec; 88(6):2744-53. PubMed ID: 8252687 [TBL] [Abstract][Full Text] [Related]
31. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia. Stein EA; Heimann KW S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650 [TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Zhao XQ; Morse JS; Dowdy AA; Heise N; DeAngelis D; Frohlich J; Chait A; Albers JJ; Brown BG Am J Cardiol; 2004 Feb; 93(3):307-12. PubMed ID: 14759379 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia. Vecchio TJ; Linden CV; O'Connell MJ; Heilman J Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415 [TBL] [Abstract][Full Text] [Related]
35. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. Schulman KA; Kinosian B; Jacobson TA; Glick H; Willian MK; Koffer H; Eisenberg JM JAMA; 1990 Dec; 264(23):3025-33. PubMed ID: 2123013 [TBL] [Abstract][Full Text] [Related]
36. Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia. Grundy SM; Mok HY J Lab Clin Med; 1977 Feb; 89(2):354-66. PubMed ID: 833472 [TBL] [Abstract][Full Text] [Related]
37. Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial. Rajah SM; Salter MC; Donaldson DR; Subba Rao R; Boyle RM; Partridge JB; Watson DA J Thorac Cardiovasc Surg; 1985 Sep; 90(3):373-7. PubMed ID: 3897722 [TBL] [Abstract][Full Text] [Related]
38. Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin. Glueck CJ; Fallat RW; Mellies M; Tsang RC Pediatrics; 1976 Jan; 57(1):68-74. PubMed ID: 174057 [TBL] [Abstract][Full Text] [Related]
39. Cholesterol-lowering effect of colestipol hydrochloride given twice daily in hypercholesterolemic patients. Gundersen K; Cooper EE; Ruoff G; Nikolai T; Assenzo JR Atherosclerosis; 1976; 25(2-3):303-10. PubMed ID: 795441 [TBL] [Abstract][Full Text] [Related]
40. Factors influencing the formation of new human coronary lesions: age, blood pressure, and blood cholesterol. Mack WJ; Blankenhorn DH Am J Public Health; 1991 Sep; 81(9):1180-4. PubMed ID: 1951831 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]